2
Investors
About
PanTarg develops antibody-drug conjugates (ADCs) with pan-cancer potential that target both cancer cells and tumor-supportive stroma, focusing on pancreatic cancer and other difficult-to-treat solid tumors.
Explore PanTarg's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.